REVIZINONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H29N5O3
Molecular Weight	459.5402
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C1CCCCC1)C(=O)CO\N=C(/C2=CC=CC=C2)C3=CC=C4N=C5NC(=O)CN5CC4=C3

InChI

InChIKey=VHDUUXNHZLBGHQ-XLVZBRSZSA-N

InChI=1S/C26H29N5O3/c1-30(21-10-6-3-7-11-21)24(33)17-34-29-25(18-8-4-2-5-9-18)19-12-13-22-20(14-19)15-31-16-23(32)28-26(31)27-22/h2,4-5,8-9,12-14,21H,3,6-7,10-11,15-17H2,1H3,(H,27,28,32)/b29-25+

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800001304 | https://www.ncbi.nlm.nih.gov/pubmed/1530374 | https://www.ncbi.nlm.nih.gov/pubmed/7669959 | https://www.ncbi.nlm.nih.gov/pubmed/7943708

Revizinone (R-80122) is a selective phosphodiesterase (PDE) III inhibitor, developed for use in treatment of heart failure and ischaemic heart disorders. Revizinone showed positive inotropic and possibly moderate vasodilating properties in dogs, and it was concluded that revizinone has a clinically favorable cardiovascular profile for acute applications in heart failure. In patients with impaired left ventricular function, revizinone was also found to be a potent positive inotropic agent. The drug was safe, its use not associated with marked vasodilation, and no positive chronotropic effects were reported.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 61 Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1328613	Inhibitor 8504		0.036 µM [IC50]
Phosphodiesterase 4 54 Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1328613	Inhibitor 8504		103.0 µM [IC50]

Name

Type

Language

REVIZINONE

Official Name

English

revizinone [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744